Pasteurella multocida

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Pasteurella
Scientific classification
Kingdom:
Bacteria
Phylum:
Proteobacteria
Class:
Gamma Proteobacteria
Order:
Pasteurellales
Family:
Pasteurellaceae
Genus:
Pasteurella
Species

Pasteurella multocida

Lua error in Module:Taxonbar/candidate at line 22: attempt to index field 'wikibase' (a nil value).

Pasteurella multocida is a Gram-negative, nonmotile, penicillin-sensitive coccobacillus belonging to the Pasteurellaceae family.[1] Strains belonging to the species are currently classified into five serogroups (A, B, D, E, F) based on capsular composition and 16 somatic serovars (1-16). P. multocida is the cause of a range of diseases in mammals and birds, including fowl cholera in poultry, atrophic rhinitis in pigs, and bovine hemorrhagic septicemia in cattle and buffalo. It can also cause a zoonotic infection in humans, which typically is a result of bites or scratches from domestic pets. Many mammals (including domestic cats and dogs) and birds harbor it as part of their normal respiratory microbiota.

History

Pasteurella multocida was first found in 1878 in cholera-infected birds. However, it was not isolated until 1880, by Louis Pasteur, in whose honor Pasteurella is named.[2]

Disease

See: Pasteurellosis

P. multocida causes a range of diseases in wild and domesticated animals, as well as humans. The bacterium can be found in birds, cats, dogs, rabbits, cattle, and pigs. In birds, P. multocida causes avian or fowl cholera disease; a significant disease present in commercial and domestic poultry flocks worldwide, particularly layer flocks and parent breeder flocks. P. multocida strains that cause fowl cholera in poultry typically belong to the serovars 1, 3, and 4. In the wild, fowl cholera has been shown to follow bird migration routes, especially of snow geese. The P. multocida serotype-1 is most associated with avian cholera in North America, but the bacterium does not linger in wetlands for extended periods of time.[3] P. multocida causes atrophic rhinitis in pigs;[4] it also can cause pneumonia or bovine respiratory disease in cattle.[5][6] In humans, P. multocida is the most common cause of infection from wound infections after dog or cat bites. The infection usually shows as soft tissue inflammation within 24 hours. High leukocyte and neutrophil counts are typically observed, leading to an inflammatory reaction at the infection site (generally a diffuse, localized cellulitis).[7] It can also infect other locales, such as the respiratory tract, and is known to cause regional lymphadenopathy (swelling of the lymph nodes). In more serious cases, a bacteremia can result, causing an osteomyelitis or endocarditis. The bacteria may also cross the blood–brain barrier and cause meningitis.[8]

Virulence, culturing, and metabolism

P. multocida expresses a range of virulence factors including a polysaccharide capsule and the variable carbohydrate surface molecule, lipopolysaccharide (LPS). The capsule has been shown in strains belonging to serogroups A and B to help resist phagocytosis by host immune cells and capsule type A has also been shown to help resist complement-mediated lysis.[9][10] The LPS produced by P. multocida consists of a hydrophobic lipid A molecule (that anchors the LPS to the outer membrane), an inner core, and an outer core, both consisting of a series of sugars linked in a specific way. There is no O-antigen on the LPS and the molecule is similar to LPS produced by Haemophilus influenzae and the lipooligosaccharide of Neisseria meningitidis. A study in a serovar 1 strain showed that a full-length LPS molecule was essential for the bacteria to be fully virulent in chickens.[11] Strains that cause atrophic rhinitis in pigs are unique as they also have P. multocida toxin (PMT) residing on a bacteriophage. PMT is responsible for the twisted snouts observed in pigs infected with the bacteria. This toxin activates Rho GTPases, which bind and hydrolyze GTP, and are important in actin stress fiber formation. Formation of stress fibers may aid in the endocytosis of P. multocida. The host cell cycle is also modulated by the toxin, which can act as an intracellular mitogen.[12] P. multocida has been observed invading and replicating inside host amoebae, causing lysis in the host. P. multocida will grow at 37 °C on blood or chocolate agar, but will not grow on MacConkey agar. Colony growth is accompanied by a characteristic "mousy" odor due to metabolic products.
Being a facultative anaerobe, it is oxidase-positive and catalase-positive, and can also ferment a large number carbohydrates in anaerobic conditions.[8] The survival of P. multocida bacteria has also been shown to be increased by the addition of salt into their environments. Levels of sucrose and pH also have been shown to have minor effects on bacterial survival.[13]

Diagnosis and treatment

Diagnosis of the bacterium in humans was traditionally based on clinical findings, and culture and seriological testing, but false negatives have been a problem due to easy death of P. multocida, and serology cannot differentiate between current infection and previous exposure. The quickest and most accurate method for confirming an active P. multocida infection is molecular detection using polymerase chain reaction.[14] This bacterium can be effectively treated with beta-lactam antibiotics, which inhibit cell wall synthesis. It can also be treated with fluoroquinolones or tetracyclines; fluoroquinolones inhibit bacterial DNA synthesis and tetracyclines interfere with protein synthesis by binding to the bacterial 30S ribosomal subunit. Despite poor in vitro susceptibility results, macrolides (binding to the ribosome) also can be applied, certainly in the case of pulmonary complications. Due to the polymicrobial etiology of P. multocida infections, treatment requires the use of antimicrobials targeted at the elimination of both aerobic and anaerobic, Gram-negative bacteria. As a result, amoxicillin-clavulanate (a beta-lactamase inhibitor/penicillin combination) is seen as the treatment of choice.[15]

Current research

P. multocida mutants are being researched for their ability to cause diseases. In vitro experiments show the bacteria respond to low iron. Vaccination against progressive atrophic rhinitis was developed by using a recombinant derivative of P. multocida toxin. The vaccination was tested on pregnant gilts (female swine without previous litters). The piglets born to treated gilts were inoculated, while the piglets born to unvaccinated mothers developed atrophic rhinitis.[16] Other research is being done on the effects of protein, pH, temperature, NaCl, and sucrose on P. multocida development and survival in water. The research seems to show the bacteria survive better in 18 °C water compared to 2 °C water. The addition of 0.5% NaCl also aided bacterial survival, while the sucrose and pH levels had minor effects, as well.[17] Research has also been done on the response of P. multocida to the host environment. These tests use DNA microarrays and proteomics techniques. P. multocida-directed mutants have been tested for their ability to produce disease. Findings seem to indicate the bacteria occupy host niches that force them to change their gene expression for energy metabolism, uptake of iron, amino acids, and other nutrients. In vitro experiments show the responses of the bacteria to low iron and different iron sources, such as transferrin and hemoglobin. P. multocida genes that are upregulated in times of infection are usually involved in nutrient uptake and metabolism. This shows true virulence genes may only be expressed during the early stages of infection.[18]

Genetic transformation is the process by which a recipient bacterial cell takes up DNA from a neighboring cell and integrates this DNA into the recipient’s genome. P. multocida DNA contains high frequencies of putative DNA uptake sequences (DUSs) identical to those in Hemophilus influenzae that promote donor DNA uptake during transformation.[19] The location of these sequences in P. multocida shows a skewed distribution towards genome maintenance genes, such as those involved in DNA repair. This finding suggests that P. multocida might be competent to undergo transformation under certain conditions, and that genome maintenance genes in transforming donor DNA may preferentially replace their damaged counterparts in the DNA of the recipient cell.[19]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Blanchlong, JA. “Persistence of pasteurella multocida in wetlands following avian cholera outbreaks.” Journal of Wildlife diseases, vol.42, no.1 (33-39)
  4. ↑ Eliás B, Hámori D. Data on the aetiology of swine atrophic rhinitis. V. The role of genetic factors. Acta Vet Acad Sci Hung. 1976;26(1):13–19. [PubMed]
  5. ↑ Irsik, M B Bovine respiratory disease associated with Mannheimia Haemolytica or pastuerella multocida. VM 163, University of Florida
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ 8.0 8.1 Casolari C, Fabio U. Isolation of Pasteurella multocida from Human Clinical Specimens: First Report in Italy. European Journal of Epidemiology. Sept 1988; 4(3):389-90
  9. ↑ [ Chung JY, Wilkie I, Boyce JD, Townsend KM, Frost AJ, Ghoddusi M, Adler B: Role of capsule in the pathogenesis of fowl cholera caused by Pasteurella multocida serogroup A. Infect Immun 2001, 69(4):2487-2492.
  10. ↑ [ Boyce JD, Adler B: The capsule is a virulence determinant in the pathogenesis of Pasteurella multocida M1404 (B:2). Infect Immun 2000, 68(6):3463-3468.
  11. ↑ [Harper M,Cox, AD, St Michael F, Wilkie IW, Boyce JD, Adler B. A heptosyltransferase mutant of Pasteurella multocida produces a truncated lipopolysaccharide structure and is attenuated in virulence. Infect. Immun. 2004; 72(6):3436-43.
  12. ↑ [Lacerda HM, Lax AJ, Rozenqurt E. Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. J Biol Chem. 5 Jan 1996; 271(1):439-45.
  13. ↑ Bredy, JP. “The effects of six environmental variables on Pasteurella multocida populations in water.” Journal of Wildlife Diseases, vol. 25, no. 2 (232-239)
  14. ↑ Miflin, J.K. and Balckall, P.J. (2001) Development of a 23 SrRNA-based PCR assay for the identification of Pasteurella multocida. Lett. Appl. Microbiol. 33: 216-221
  15. ↑ Red Book: 2006 Report of the Committee on Infectious Diseases - 27th Ed.
  16. ↑ Nielsen JP Vaccination against progressive atrophic rhinitis with a recombinant “Pasteurella multocida” toxin derivative. Canadian Journal of Veterinary Research, vol.55, no.2 (128-138)
  17. ↑ Bredy, JP. The effects of six environmental variables on P. multocida populations in water. “Journal of Wildlife Diseases”, vol. 25, no.2 (232-239)
  18. ↑ Boyce, JD. How does P. multocida respond to the host environment? “Current Opinion in Microbiology” vol.9 no.1 (117-122)
  19. ↑ 19.0 19.1 Lua error in package.lua at line 80: module 'strict' not found.

External links

Retrieved from "https://infogalactic.com/w/index.php?title=Pasteurella_multocida&oldid=4453942"